The US Food and Drug Administration is trying to shoehorn real-world data into existing technical standards that are better-suited to clinical trial data, pharmaceutical industry stakeholders and data companies say.
In comments on the FDA’s draft guidance on data standards for drug submissions containing real-world data, stakeholders raise concerns about the loss of detail that can result from having...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?